TUMORGEN, INC.

Medtech · Defunct

Microfluidic device that captures and characterizes circulating metastatic cancer cell clusters from patient blood using dual-capture technology (biomimicry + immunocapture)

Grants
$393K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
1 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Capture and Characterization of Highly Metastatic Cancer Cell Clusters in Transit from Lung Cancer Patient Whole Blood Specimens.$393,048
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1632PLACENTAL ANALYTICS, LLC——
1633IGE IMMUNO DIAGNOSTIC SYSTEMS, INC.——
1634CUTCATH LLC——
1635TUMORGEN, INC.——
1636Bioretec Ltd—$4.1M
1637ZENWA,INCORPORATED——
1638Prescient Surgical——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 3

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.